Regarding NSCLC, mutations in EGFR are considered to be standard predictive biomarkers being indicative of treatment response and constituting the basis for the development of alternative targeted therapies, namely, EGFR tyrosine kinase inhibitors (EGFR TKIs) [9,10]. Here, EGFR is linked to non-small cell lung carcinoma.